|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Streptococcus pneumoniae</i> is a major cause of pneumonia, wherein infection of respiratory mucosa drives a robust influx of neutrophils.We have previously shown that <i>S. pneumoniae</i> infection of the respiratory epithelium induces the production of the 12-lipoxygenase (12-LOX)-dependent lipid inflammatory mediator hepoxilin A3, which promotes recruitment of neutrophils into the airways, tissue damage, and lethal septicemia.
|
31776202 |
2020 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Streptococcus pneumoniae</i> is a major cause of pneumonia, wherein infection of respiratory mucosa drives a robust influx of neutrophils.We have previously shown that <i>S. pneumoniae</i> infection of the respiratory epithelium induces the production of the 12-lipoxygenase (12-LOX)-dependent lipid inflammatory mediator hepoxilin A3, which promotes recruitment of neutrophils into the airways, tissue damage, and lethal septicemia.
|
31776202 |
2020 |
|
Refractory cancer
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
15-LOX-1 has diverse roles in the resensitization of resistant cancer cell lines to doxorubicin.
|
31663148 |
2020 |
|
Airway Obstruction
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, co-administration of submaximal doses of the TRPV1 and TRPA1 antagonists or the COX and 12-LOX inhibitors resulted in a greater inhibition of both cough reflex and airway obstruction.
|
31170972 |
2019 |
|
Coughing
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, co-administration of submaximal doses of the TRPV1 and TRPA1 antagonists or the COX and 12-LOX inhibitors resulted in a greater inhibition of both cough reflex and airway obstruction.
|
31170972 |
2019 |
|
Craniosynostosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Most notably, a missense variant in ALOX15 that causes a p.Thr560Met alteration in arachidonate 15-lipoxygenase (15-LO) confers large genome-wide significant protection against NP (P = 8.0 × 10<sup>-27</sup>, odds ratio = 0.32; 95% confidence interval = 0.26, 0.39) and CRS (P = 1.1 × 10<sup>-8</sup>, odds ratio = 0.64; 95% confidence interval = 0.55, 0.75). p.Thr560Met, carried by around 1 in 20 Europeans, was previously shown to cause near total loss of 15-LO enzymatic activity.
|
30643255 |
2019 |
|
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
COX1 and ALOX12B expression, COX and 12/15-LOX metabolites as well as various lipids, which are known to induce itch (12-HETE, LTB4, TXB2, PGE2 and PGF2) and the ratio of pro-inflammatory vs pro-resolving lipid mediators in non-affected and affected skin as well as in the serum of AD patients were increased, while n3/n6-PUFAs and metabolite ratios were lower in non-affected and affected AD skin.
|
30575130 |
2019 |
|
Eczema
|
0.010 |
Biomarker
|
disease |
BEFREE |
COX1 and ALOX12B expression, COX and 12/15-LOX metabolites as well as various lipids, which are known to induce itch (12-HETE, LTB4, TXB2, PGE2 and PGF2) and the ratio of pro-inflammatory vs pro-resolving lipid mediators in non-affected and affected skin as well as in the serum of AD patients were increased, while n3/n6-PUFAs and metabolite ratios were lower in non-affected and affected AD skin.
|
30575130 |
2019 |
|
Enteritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further findings pointed out that hucMSCs transfected with miR148b-5p mimics could be elevated to promote the tissue repair and inhibit the expression of 15-lox-1 but failed to perform the function of easing enteritis when treated with miR148b-5p inhibitors.
|
31275059 |
2019 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
It was concluded that baicalein exerted neuroprotective effects against posttraumatic epileptic seizures <i>via</i> suppressing ferroptosis and 12/15-LOX was likely to be involved in baicalein's neuroprotection.
|
31231224 |
2019 |
|
Mesothelioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We aimed to examine 5-LOX and 12-LOX protein expression in a large retrospective series of mesothelioma samples.
|
30941737 |
2019 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The studies with the use of knockout and transgenic animals for 12/15-LOX have further shown its involvement in the pathogenesis of a variety of human diseases, including cardiovascular, renal, neurological and metabolic disorders.
|
30472260 |
2019 |
|
Dental Fluorosis, Acquired
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association between ALOX15 gene polymorphism and brick-tea type skeletal fluorosis in Tibetans, Kazaks and Han, China.
|
31565963 |
2019 |
|
Nematode infections
|
0.010 |
Biomarker
|
group |
BEFREE |
In contrast, high levels of cysteinyl leukotrienes (cysLTs) and 12-/15-LOX metabolites were produced in the airways during AAI or nematode infection in mice.
|
30554425 |
2019 |
|
Rett Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of 9- and 13-HODEs were elevated in RTT and associated with the expression of arachidonate 15-Lipoxygenase (ALOX15) in peripheral blood mononuclear cells (PBMCs).
|
30743046 |
2019 |
|
Subarachnoid Hemorrhage
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neuronal cell death after SAH was reduced by ML351 and in Alox15 knockout mice.
|
30602353 |
2019 |
|
Complications of Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we describe the function and role of human 12-LOX, and mouse 12-LOX and 12/15-LOX, in the development of diabetes and diabetes-related complications, and describe promise in the development of strategies to limit pro-inflammatory metabolites, primarily via new small molecule 12-LOX inhibitors.
|
30347209 |
2019 |
|
Bacterial keratitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exploring the immunoresolving role of FPR2, its ligand RvD1 and related enzymes (5-LOX, 12/15-LOX), our results suggest a mechanism by which VIP treatment influences the disease response in bacterial keratitis, which could offer a therapeutic point of intervention for enhancing this pro-resolving circuit.
|
30529189 |
2019 |
|
Pleural mesothelioma malignant advanced
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of 5-LOX with 12-LOX was seen in 46/78 (58%) of MPM samples.
|
30941737 |
2019 |
|
SCAPULOPERONEAL MYOPATHY, X-LINKED DOMINANT
|
0.010 |
Biomarker
|
disease |
BEFREE |
Besides expected on-target actions, we found that: <i>1</i>) COX or 15-LOX-1 inhibitors elevate inflammatory leukotriene levels, <i>2</i>) FLAP and 5-LOX inhibitors reduce leukotrienes in M1 but less so in M2 macrophages, <i>3</i>) zileuton blocks resolution-initiating SPM biosynthesis, whereas FLAP inhibition increases SPM levels, and <i>4</i>) that the 15-LOX-1 inhibitor 3887 suppresses SPM formation in M2 macrophages.
|
30735438 |
2019 |
|
Epileptic Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
It was concluded that baicalein exerted neuroprotective effects against posttraumatic epileptic seizures <i>via</i> suppressing ferroptosis and 12/15-LOX was likely to be involved in baicalein's neuroprotection.
|
31231224 |
2019 |
|
Chronic rhinosinusitis with nasal polyps
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the role of ALOX15 during the EMT process in CRSwNP.
|
30452122 |
2019 |
|
Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Alox15 KO resulted in loss of hair follicle stem cells and abnormal transition of dermal adipocytes into fibroblasts.
|
29891910 |
2018 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vitro experiments performed on amyloid vascular smooth muscle cells showed that a 12-LOX inhibitor almost completely blocked the Aβ<sub>1-40</sub> peptide-induced apoptosis of these cells.
|
29620941 |
2018 |
|
Merkel cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, all 17 samples of MCC metastases showed ALOX15 expression with a median lymphatic vessel density (not lymph node metastases) of 5.3 (range 2.0-7.3).
|
29992788 |
2018 |